GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » 3-Year EPS without NRI Growth Rate

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) 3-Year EPS without NRI Growth Rate : -22.80% (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co 3-Year EPS without NRI Growth Rate?

Chongqing Genrix Biopharmaceutical Co's EPS without NRI for the three months ended in Mar. 2025 was ¥-0.33.

During the past 3 years, the average EPS without NRI Growth Rate was -22.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Chongqing Genrix Biopharmaceutical Co was -22.80% per year. The lowest was -22.80% per year. And the median was -22.80% per year.


Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's 3-Year EPS without NRI Growth Rate falls into.


;
;

Chongqing Genrix Biopharmaceutical Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Chongqing Genrix Biopharmaceutical Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines